• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169518 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  6 Y. X; u5 N$ K' Y

+ c- l  V9 _# K: \% F
1 U1 k9 S0 z. t1 U! Q- NSub-category:3 Y7 |' m- [$ L% K% a
Molecular Targets
  d/ h5 g- j9 m+ ^- z9 s' `  O
7 F6 z6 N: Y5 `* P3 S
% {" V: K) D" V1 qCategory:1 K/ d! ?# u! a1 \# [: j8 H) W  I
Tumor Biology
0 B+ n( t7 r$ I. K) K9 h* g6 v( x9 E  O& r' F8 d  t
7 r- J# e9 S1 \
Meeting:
3 x6 @$ z, n+ M4 |2 o% R) @6 F3 i2011 ASCO Annual Meeting 5 G! B0 t$ ~/ o) ]5 j
- j! p* Q; L1 u* }/ F* {( f

5 P: X1 p& x" L, x2 {9 A. ]2 S. X0 zSession Type and Session Title:3 M4 }6 B  g2 H* X# a; e7 h
Poster Discussion Session, Tumor Biology
+ U3 T; P! i5 v* f- T6 u8 o/ G) G" a% R

7 |9 I6 v: q) m5 e7 yAbstract No:" d! E$ E0 ?4 s0 B, t$ {
10517 ( t. I6 D. j5 a

: M6 }2 O3 i  y! M& J  x8 z2 u: ]2 W" M
Citation:
+ D' d) q! w: O( hJ Clin Oncol 29: 2011 (suppl; abstr 10517)
5 c: s: l, F" n6 t
: }# F% y& C- c% n! I* P. @! w5 s1 N5 e, t1 x4 g  I$ S9 J' E" {
Author(s):6 ^7 f8 O8 |7 X+ e
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 J" Q: s; C: H, t$ ]; `) {2 |# d! s3 O5 H  O, t

. P8 L) _& u- a
2 m' z) n& s- o  ^$ n3 T/ Q1 YAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.+ b# q5 ~3 s5 \& ]+ h/ w

& K: i6 m! \! s* l; ]* fAbstract Disclosures7 C& o: c1 P+ t- e( L% _( _- G
+ q4 C  N  V2 g( h* ^# s2 y/ A" ^5 d
Abstract:
4 g6 |+ g/ S7 G0 S: E; S
- C6 R- U( z- b* U5 j2 w5 G, G/ A4 t
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 q; Y5 ]9 ~! |3 _* K- z4 d( d5 h& f, {1 i

  H6 S/ U  l7 D8 O
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
0 u% K! \( R- A9 t: w没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
) r8 m" J8 k# e; _6 C" J
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ; e1 c( r- B! ?! f# q  T
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。' W0 x; K0 L3 l; h
ALK一个指标医院要900多 ...

! h0 G( l! R3 y0 J4 w+ \6 D平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 Y7 E7 F. a3 e; o

, [3 m% x5 |3 `' L9 T现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表